Every material Form 8-K Royalty Pharma plc has filed with the SEC since May 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Royalty Pharma reported third quarter 2026 Portfolio Receipts of $890 million, up 9% from a year earlier, and raised its full-year 2026 Portfolio Receipts guidance to $3,500 million to $3,550 million. Net income attributable to Royalty Pharma plc fell to $145 million from $284 million, mainly because of a $150 million non-cash impairment on pelacarsen after a Phase 3 trial missed its primary endpoint.
Portfolio Receipts rose 9% to $890 million; Royalty Receipts rose 9% to $883 million.
2026 Portfolio Receipts guidance raised to $3,500 million to $3,550 million from $3,400 million to $3,500 million.
Net income attributable to Royalty Pharma plc was $145 million, versus $284 million a year earlier, after a $150 million impairment tied to pelacarsen.
Net cash provided by operating activities was $686 million, down 2% from $703 million.
Royalty Pharma reported second-quarter 2026 results on August 5, 2026 and raised its full-year 2026 Portfolio Receipts guidance to $3,400 million to $3,500 million, from $3,325 million to $3,450 million. Portfolio Receipts rose 6% to $773 million and Royalty Receipts rose 14%, but net income attributable to Royalty Pharma plc fell to $18 million from $32 million, which included a $268 million provision for changes in expected cash flows from financial royalty assets.
Q2 2026 Portfolio Receipts were $773 million, up 6% from $727 million; Royalty Receipts grew 14% to $768 million.
Full-year 2026 Portfolio Receipts guidance raised to $3,400 million to $3,500 million from $3,325 million to $3,450 million.
Net income attributable to Royalty Pharma plc was $18 million, down from $32 million; Adjusted EBITDA rose 16% to $736 million.
Company repurchased $45 million of Class A shares in Q2 2026 and held $812 million in cash as of June 30, 2026.
On May 22, 2026, Royalty Pharma signed a new $1.8 billion unsecured revolving credit agreement with Bank of America, N.A. as administrative agent, replacing its September 15, 2021 facility in full. The new facility matures May 22, 2031, and the filing lists financial covenants that shareholders can track.
Facility size is $1.8 billion, unsecured, with Bank of America, N.A. as administrative agent
Replaces the Existing Credit Agreement dated September 15, 2021; all obligations under it were repaid and its commitments terminated
Maturity date is May 22, 2031
Covenants require a consolidated leverage ratio at or below 4.00 to 1.00 and a coverage ratio of at least 2.50 to 1.00
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Royalty Pharma plc filing is on SEC EDGAR ↗. 8-K briefs of other companies →